

IN THE CLAIMS:

Please cancel claims 1-24 and add claims 25-42 as follows:

Claims 1- 24 (Canceled).

25. (New) An antigen binding protein which binds VASP (vasodilator-stimulated phosphoprotein) as antigen when VASP is present in phosphorylated form, wherein said VASP is in the natural form or is a functionally equivalent moiety, mutant, fragment or variant thereof and wherein the antigen binding protein is a monoclonal antibody (Mab) or fragment thereof.
26. (New) The antigen binding protein of claim 1, wherein the VASP is phosphorylated at position serine 157.
27. (New) The antigen binding protein of claim 1, wherein the VASP is phosphorylated at position serine 239 (phosphoserine 239 VASP).
28. (New) The antigen binding protein of claim 1, wherein the VASP is phosphorylated at position threonine 278 (phosphothreonine 278 VASP).
29. (New) The antigen binding protein of claim 1, wherein the monoclonal antibody or the fragment thereof is a synthetic or recombinant protein.
30. (New) The antigen binding protein of claim 1, wherein the fragment of the monoclonal antibody is a natural, synthetic or recombinant F(ab)₂', Fab, Fab' or Fv fragment.
31. (New) A hybridoma cell line which produces an antigen binding protein which recognizes VASP as antigen when VASP is present in phosphorylated form, wherein said VASP is in the natural form or is a functionally equivalent moiety, mutant, fragment or variant thereof and

wherein the antigen binding protein is a monoclonal antibody (Mab) or fragment thereof.

32. (New) The hybridoma cell line of claim 31, wherein the VASP is phosphorylated at position serine 157.
33. (New) The hybridoma cell line of claim 31, wherein the VASP is phosphorylated at position serine 239 (phosphoserine 239 VASP).
34. (New) The hybridoma cell line of claim 31, wherein the VASP as antigen, when VASP is phosphorylated at position threonine 278 (phosphothreonine 278 VASP).
35. (New) The hybridoma cell line of claim 31, wherein the monoclonal antibody or the fragment thereof is a synthetic or recombinant protein.
36. (New) The hybridoma cell line of claim 31, wherein the fragment of the monoclonal antibody is a natural, synthetic or recombinant F(ab)₂', Fab, Fab' or Fv fragment.
37. (New) A diagnostic kit, comprising an antigen binding protein which recognizes VASP as antigen when VASP is present in phosphorylated form, wherein said VASP is in the natural form or is a functionally equivalent moiety, mutant, fragment or variant thereof and wherein the antigen binding protein is a monoclonal antibody (Mab) or fragment thereof.
38. (New) The diagnostic kit of claim 37, wherein the VASP is phosphorylated at position serine 157.
39. (New) The diagnostic kit of claim 37, wherein the VASP is phosphorylated at position serine 239 (phosphoserine 239 VASP).

40. (New) The diagnostic kit of claim 37, wherein the VASP is phosphorylated at position threonine 278 (phosphotreonine 278 VASP).
41. (New) The diagnostic kit of claim 37, wherein the monoclonal antibody or the fragment thereof is a synthetic or recombinant protein.
42. (New) The diagnostic kit of claim 37, wherein the fragment of the monoclonal antibody is a natural, synthetic or recombinant F(ab)₂', Fab, Fab' or Fv fragment.